Over the years, scientists have explored alternatives to Cas9, such as Cas12a for more precise multigene editing, a type III CRISPR for RNA editing, and a Cas13 loaded with multiple ... Biochemist ...

Co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna, Scribe was among a second generation of gene editing companies to emerge in the late 2010s. It promised to use engineering ...

In the article, my colleague Jef Akst highlighted Doudna, Charpentier, and Zhang as the three seminal figures in the development of CRISPR/Cas9 technology: “The attendees are a veritable who’s who of ...

CRISPR co-creator Jennifer Doudna on watching her groundbreaking gene-editing technology help sickle cell patients: “It’s extraordinary.” Jennifer Doudna codeveloped the revolutionary gene ...

We demonstrate that RNA-targeting CRISPR effector Cas13 can be engineered for RNA diagnostics and mammalian cell RNA knockdown, binding, and editing. We demonstrate diagnostic applications of Cas13 ...

The foundation had been in touch with Doudna, who pointed the foundation to Wilson, who was initially skeptical because CRISPR brain cancer therapies have proved difficult. But Wilson did more ...

Drs Emmanuelle Charpentier and Jennifer Doudna have won this year’s Nobel Prize for chemistry in recognition of their work on the gene-editing technology CRISPR/Cas9. Charpentier – currently ...

The five-year deal with CRISPR co-inventor Jennifer Doudna of UC Berkeley and Jonathan Weissman of UC San Francisco includes $67 million in funding for a Laboratory for Genomics Research (LGR ...

CRISPR has revolutionized the biosciences over the past decade. The RNA-targeting CRISPR effector protein Cas13, discovered in 2016, opened up a myriad of new applications for CRISPR-based ...